These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 12424021)

  • 1. Interferon beta-1a and beta-1b for treatment of multiple sclerosis.
    Benatar M
    Lancet; 2002 Nov; 360(9343):1428; author reply 1428-9. PubMed ID: 12424021
    [No Abstract]   [Full Text] [Related]  

  • 2. [Clinical efficacy and safety of long-term immunomodulating therapy with interferon beta].
    Demina TL; Khachanova NV; Davydovskaia MV; Popova NF; Gusev EI
    Zh Nevrol Psikhiatr Im S S Korsakova; 2008; 108(4):24-6. PubMed ID: 18567192
    [No Abstract]   [Full Text] [Related]  

  • 3. [High doses of interferon in the treatment of multiple sclerosis].
    Muñoz D
    Rev Neurol; 2001 May 1-15; 32(9):899. PubMed ID: 11424041
    [No Abstract]   [Full Text] [Related]  

  • 4. Interferon beta-1A: new preparation. A short-term impact on the course of multiple sclerosis.
    Prescrire Int; 1998 Oct; 7(37):142-3. PubMed ID: 10915418
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [10 years of interferon treatment in multiple sclerosis. Does the future belong to high-dose therapy?].
    MMW Fortschr Med; 2003 May; 145 Suppl 2():108. PubMed ID: 14579501
    [No Abstract]   [Full Text] [Related]  

  • 6. Treatment of multiple sclerosis with interferon beta 1b.
    Dhib-Jalbut S; McFarland HF
    Baillieres Clin Neurol; 1997 Oct; 6(3):467-80. PubMed ID: 10101584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interferon beta-1a and beta-1b for treatment of multiple sclerosis.
    Kappos L
    Lancet; 2002 Nov; 360(9343):1428; author reply 1428-9. PubMed ID: 12424020
    [No Abstract]   [Full Text] [Related]  

  • 8. Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial.
    Comi G; De Stefano N; Freedman MS; Barkhof F; Polman CH; Uitdehaag BM; Casset-Semanaz F; Hennessy B; Moraga MS; Rocak S; Stubinski B; Kappos L
    Lancet Neurol; 2012 Jan; 11(1):33-41. PubMed ID: 22146409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A comparative analysis of rebif 22-mcg and copaxone efficacy in multiple sclerosis].
    Zavalishin IA; Peresedova AV; Stoĭda NI; Rebrova Oi; Zakharova MN; Adarcheva LS; Niazbekova AS; Askarova LSh; Baĭdina EV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2006; Spec No 3():111-5. PubMed ID: 17172245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis.
    Schwid SR; Panitch HS
    Clin Ther; 2007 Sep; 29(9):2031-48. PubMed ID: 18035202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glatiramer acetate versus interferon beta-1a for subcutaneous administration: comparison of outcomes among multiple sclerosis patients.
    Castelli-Haley J; Oleen-Burkey M; Lage MJ; Johnson KP
    Adv Ther; 2008 Jul; 25(7):658-73. PubMed ID: 18641926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of prolonged immunomodulatory treatment with interferon beta.
    Demina TL; Khachanova NV; Davydovskaya MV; Popova NF; Gusev EI
    Neurosci Behav Physiol; 2009 Jun; 39(5):497-9. PubMed ID: 19430980
    [No Abstract]   [Full Text] [Related]  

  • 13. [Therapeutic potential of interferon beta-1b and related drugs in multiple sclerosis: comparative meta-analysis].
    Cendrowski W
    Neurol Neurochir Pol; 2001; 35(4 Suppl):125-38. PubMed ID: 11873611
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interferon beta treatment in relapsing-remitting multiple sclerosis. A review.
    Grigoriadis N
    Clin Neurol Neurosurg; 2002 Jul; 104(3):251-8. PubMed ID: 12127664
    [No Abstract]   [Full Text] [Related]  

  • 15. [Interferon beta-1a].
    Taéron C
    Rev Infirm; 2004 May; (101):39-40. PubMed ID: 15984751
    [No Abstract]   [Full Text] [Related]  

  • 16. 10 years of interferon beta-1b (Beta feron therapy.
    Kappos L; Hartung HP
    J Neurol; 2005 Sep; 252 Suppl 3():iii1-iii2. PubMed ID: 16170493
    [No Abstract]   [Full Text] [Related]  

  • 17. Long-term benefits of early and high doses of interferon beta-1a treatment in relapsing-remitting multiple sclerosis.
    Chofflon M; Ben-Amor AF
    Clin Neurol Neurosurg; 2002 Jul; 104(3):244-8. PubMed ID: 12127662
    [No Abstract]   [Full Text] [Related]  

  • 18. [Interferon therapy of multiple sclerosis].
    Jensen D
    Tidsskr Nor Laegeforen; 1999 Sep; 119(21):3142-5. PubMed ID: 10522481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effective treatment of multiple sclerosis with rebif-22 mcg in children and adolescences: results of a long-term study].
    Bykova OV; Studenikin VM; Kuzenkova LM; Maslova OI; Boĭko AN
    Zh Nevrol Psikhiatr Im S S Korsakova; 2006; Spec No 3():116-21. PubMed ID: 17172246
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferon beta-1b and childhood multiple sclerosis.
    Adams AB; Tyor WR; Holden KR
    Pediatr Neurol; 1999 Jul; 21(1):481-3. PubMed ID: 10428435
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.